TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18454224
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate 150 mg twice daily
Study: 18454224
Drug: Dapsone 50
Normalized name: dapsone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone 50 mg twice daily
Study: 18454224
Drug: Glucose 250
Normalized name: glucose 250 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose 250 mg as placebo
Study: 18425652
Drug: Dietary fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary fat restriction (22-26 g/day)
Study: 1753937
Drug: Local and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local and systemic treatment with salcatonin
Study: 17580516
Drug: Colchicine as
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine as adjunct to conventional treatment
Study: 16145640
Drug: Tramadol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 1.5 mg/kg added to 40 ml prilocaine 1.5%
Study: 16145640
Drug: Clonidine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 1.5 microg/kg added to 40 ml prilocaine 1.5%
Study: 16145640
Drug: Prilocaine 1.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prilocaine 1.5% without additional medication (Control)
Study: 11835111
Drug: Sodium profile
Normalized name: PROFIMER SODIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium profile (decreasing sodium concentration from 145 to 133 mmol/L)
Study: 11835111
Drug: Constant sodium
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant sodium concentration (138 mmol/L)
Study: 31626156
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy + VR (15 minutes twice daily for 10 days)
Study: 28629351
Drug: HRQOL assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRQOL assessment considered important in daily work
Study: 19704066
Drug: Fulvestrant 500
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant 500 mg/mo (plus 500 mg on day 14 of month 1)
Study: 16009955
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg/d
Study: 17273013
Drug: Lavender essential
Normalized name: Nature's Truth Lavender Essential Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lavender essential oil for inhalation
Study: 17273013
Drug: Inert oil
Normalized name: inert ingredients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert oil (placebo) for inhalation
Study: 12388962
Drug: Extra-amniotic saline
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-amniotic saline solution infusion
Study: 8265095
Drug: 32 mg
Normalized name: caffeine 32 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 mg ondansetron
Study: 19395466
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg granisetron
Study: 3663434
Drug: Meptazinol 20
Normalized name: meptazinol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptazinol 20 mg
Study: 3663434
Drug: Meptazinol 30
Normalized name: meptazinol
DrugBank: Meptazinol (DB13478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptazinol 30 mg
Study: 3663434
Drug: Meptazinol 48
Normalized name: meptazinol
DrugBank: Meptazinol (DB13478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptazinol 48 mg
Study: 3663434
Drug: Pethidine 20
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine 20 mg
Study: 29652755
Drug: Comprehensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive treatment and rehabilitation program including preop chemotherapy, surgery, postop rehabilitation, and mesodiencephalic modulation (MDM) sessions after each invasive intervention.
Study: 25485879
Drug: Intraoperative dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative dexmedetomidine (1 μg kg(‐1) loading dose followed by 0.5 μg kg(‐1) h(‐1) continuous infusion)
Study: 22922682
Drug: Ticagrelor (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (loading dose 270 mg; 90 mg twice daily for 7 days) plus atorvastatin (80 mg on day 5)
Study: 22922682
Drug: Ticagrelor (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (loading dose 270 mg; 180 mg twice daily for 7 days) plus simvastatin (80 mg on day 5)
Study: 22922682
Drug: Ticagrelor with
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor with atorvastatin metabolites
Study: 22922682
Drug: Ticagrelor (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (single dose)
Study: 22029963
Drug: MTRX1011A at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTRX1011A at 1.5 mg/kg subcutaneously (s.c.) weekly
Study: 22029963
Drug: MTRX1011A at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTRX1011A at 3.5 mg/kg s.c. weekly
Study: 22029963
Drug: MTRX1011A at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTRX1011A at 5 mg/kg intravenously (i.v.) weekly
Study: 22029963
Drug: MTRX1011A (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTRX1011A (various doses)
Study: 17026510
Drug: Repeated professional
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated professional tooth cleaning combined with oral hygiene instruction
Study: 17026510
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene instruction only (Control)
Study: 14629059
Drug: Ropivacaine (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (higher dose)
Study: 10930965
Drug: Enzyme-inducing antiepileptic
Normalized name: lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enzyme-inducing antiepileptic drugs without valproate
Study: 2504972
Drug: Mifurol (6-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifurol (6-12 mg/kg/day) + MMC (0.2 mg/kg x 2)
Study: 2504972
Drug: Tegafur (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegafur (12 mg/kg/day) + MMC (0.2 mg/kg x 2)
Study: 969779
Drug: Choleretics administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choleretics administered orally in a dosage two to five times more than the recommended one
Study: 28234235
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor monotherapy (PI‐mono)
Study: 22791766
Drug: Concurrent PTH(1-84)
Normalized name: PTH
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Concurrent PTH(1-84) and ibandronate for 6 months followed by 18 months of ibandronate
Study: 22791766
Drug: Sequential PTH(1-84)
Normalized name: PTH
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sequential PTH(1-84) for two courses of 3 months followed by 9 months of ibandronate
Study: 22791766
Drug: Concurrent PTH(1-84)
Normalized name: PTH
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Concurrent PTH(1-84) and ibandronate
Study: 22791766
Drug: Sequential PTH(1-84)
Normalized name: PTH
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sequential PTH(1-84)
Study: 22791766
Drug: Concurrent and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent and sequential therapies
Study: 19354091
Drug: Functional Restoration
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional Restoration (FR) treatment group
Study: 19354091
Drug: Standard anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anesthesia pain clinic treatment comparison group
Study: 9818296
Drug: Acenocoumarol once
Normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acenocoumarol once daily
Study: 9818296
Drug: Acenocoumarol twice
Normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acenocoumarol twice daily
Study: 1827042
Drug: isosorbide‐5‐mononitrate (ISMN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: isosorbide‐5‐mononitrate (ISMN) 20 mg
Study: 25828636
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of irbesartan/hydrochlorothiazide FDC tablet (300/12.5 mg)
Study: 25828636
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of irbesartan/hydrochlorothiazide FDC tablet (300/12.5 mg)
Study: 21175274
Drug: Patient-led titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-led titration of insulin glargine
Study: 21175274
Drug: Physician-led titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician-led titration of insulin glargine
Study: 2604532
Drug: Classical Tetracoq
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classical Tetracoq vaccine
Study: 2604532
Drug: Inactivated poliomyelitis
Normalized name: Inactivated poliomyelitis vaccine (V.C.O.) type 2 MEF1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated poliomyelitis vaccines prepared on monkey kidney cells
Study: 2604532
Drug: Inactivated poliomyelitis
Normalized name: Inactivated poliomyelitis vaccine (V.C.O.) type 2 MEF1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated poliomyelitis vaccines prepared on Vero-type continuous cell lines
Study: 2604532
Drug: Polio vaccine
Normalized name: Oral Polio Vaccine
DrugBank: Oral Polio Vaccine (DB15864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polio vaccine placed in a 2-compartment syringe separating the polio vaccine from the DPT
Study: 1234488
Drug: Codeine phosphate
Normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine phosphate syrup, B.P.C.
Study: 1234488
Drug: Syrup alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syrup alone
Study: 26576178
Drug: Risperidone 6
Normalized name: risperidone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 6 mg/day plus Zn sulfate (50 mg elemental Zn three times a day)
Study: 21410733
Drug: AZD1386 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1386 30 mg
Study: 21410733
Drug: AZD1386 95
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1386 95 mg
Study: 17217713
Drug: Xuezhikang 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang 0.6 g Bid
Study: 14633563
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL dilute solution (0.1%/0.5 microg/mL ropivacaine/fentanyl)
Study: 14633563
Drug: 8 mL
Normalized name: ethanol 0.8 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mL concentrated solution
Study: 14633563
Drug: 12 mL
Normalized name: syringe, disposable, 12 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mL ropivacaine and 6 microg fentanyl
Study: 11084114
Drug: Ventricular resynchronization
Normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventricular resynchronization therapy (VRT) by left or biventricular stimulation
Study: 9084896
Drug: Fluoxetine and
Normalized name: fluoxetine and psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine and Maprotiline
Study: 31308644
Drug: Behavioral medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral medicine intervention in physical therapy (BMPI)
Study: 25415733
Drug: Regular dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular dose (CTDIvol, 38.4 mGy)
Study: 25415733
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose (CTDIvol, 24.6 mGy) with 30% ASIR
Study: 25415733
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose (CTDIvol, 15.4 mGy) with 50% ASIR
Study: 25415733
Drug: All ASIR
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All ASIR percentages regardless of radiation dose
Study: 22805387
Drug: Cefotaxime/heparin lock
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime/heparin lock
Study: 18065789
Drug: Standard heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard heparin lock
Study: 19124398
Drug: Olmesartan (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan (20-40 mg/day)
Study: 12087569
Drug: Once-weekly epoetin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly epoetin beta (n = 84)
Study: 12087569
Drug: Thrice-weekly epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly epoetin beta (n = 89)
Study: 9451066
Drug: Low-dose aprotinin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aprotinin (1 x 10(6) kallikrein activation units)
Study: 2527473
Drug: Propranolol (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (150 mg/day)
Study: 3294067
Drug: Pindolol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (15 mg/day)
Study: 31943297
Drug: PegIFNÎ± treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegIFNÎ± treatment for 48 weeks plus 24 weeks follow-up
Study: 31943297
Drug: NUCs treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUCs treatment for 104 weeks
Study: 28167468
Drug: Early intravenous
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intravenous nutrition therapy (Group A)
Study: 28167468
Drug: Late parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late parenteral nutrition (Group B)
Study: 21159785
Drug: Omega-3 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 supplementation (3.0 g eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) at a 5:1 ratio)
Study: 18224442
Drug: naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen 500 mg twice daily plus omeprazole 20 mg daily
Study: 18224442
Drug: naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen 500 mg twice daily plus placebo
Study: 1389761
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Atenolol and Nifedipine
Study: 10676687
Drug: Moxonidine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine 0.1 mg b.i.d. (initial dose), increased weekly to 0.2 mg and 0.3 mg b.i.d. as target doses.
Study: 10676687
Drug: Moxonidine (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine (0.1, 0.2, or 0.3 mg b.i.d.)
Study: 8452172
Drug: Oral fleroxacin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fleroxacin, 400 mg once a day for 4-21 days
Study: 8452172
Drug: Oral amoxicillin/clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin/clavulanate (AMX/CP), 400 mg/125 mg three times a day for 4-21 days
Study: 3762014
Drug: L-penbutolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-penbutolol (40 mg)
Study: 3762014
Drug: D-penbutolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-penbutolol (40 mg)
Study: 31306465
Drug: Telephone administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone administered brief HIV risk reduction intervention
Study: 28184431
Drug: Nintedanib in
Normalized name: Product containing nintedanib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib in combination with pemetrexed
Study: 23904191
Drug: Budesonide/formoterol maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol maintenance and reliever therapy (SMART™)
Study: 23904191
Drug: Free combination
Normalized name: SUNSCREEN-29 PABA-FREE COMBINATION LOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free combination of inhaled corticosteroid (ICS) + long‐acting β2‐agonist (LABA) and as‐needed short‐acting β2‐agonist (SABA)
Study: 21508090
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplementation (100 μg/d)
Study: 21508090
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplementation (4000 μg/wk)
Study: 21508090
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplementation (4000 μg/d)
Study: 17332146
Drug: MTHFR genotype
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTHFR genotype (TT vs CC)
Study: 16282699
Drug: Pamidronate (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (125 mg) + oral calcium (500 mg/day) for 3 months
Study: 16282699
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium (500 mg/day) for 3 months
Study: 11287080
Drug: Pivagabine (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivagabine (900 mg, twice a day)
Study: 3447933
Drug: RO 13-6438
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO 13-6438 (10 mg)
Study: 3447933
Drug: RO 13-6438
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO 13-6438 (20 mg)
Study: 3447933
Drug: RO 13-6438
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO 13-6438 (30 mg)
Study: 3447933
Drug: RO 13-6438
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO 13-6438 (all doses)
Study: 20825743
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and Metformin Therapy
Study: 16020407
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein 15 g/d
Study: 16020407
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein 25 g/d
Study: 8566673
Drug: Metronidazole 250mg
Normalized name: METRONIDAZOLE 250MG TAB
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole 250mg plus Amoxicillin 500mg T.I.D for 10 days
Study: 7010651
Drug: Preoperative irradiation
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative irradiation therapy (700 rads X 2)
Study: 24447296
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine at 1 μg.kg(‐1)
Study: 24447296
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine at 1.5 μg.kg(‐1)
Study: 24447296
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine at 2 μg.kg(‐1)
Study: 22915643
Drug: Hydroxyurea (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (20 mg/kg/d)
Study: 21067805
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg simvastatin daily
Study: 21067805
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg simvastatin daily
Study: 17922743
Drug: Hemoscan and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoscan and Crit‐Line combination
Study: 17922743
Drug: BVM and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: BVM and Crit‐Line combination
Study: 10068580
Drug: High-dose subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose subcutaneous interleukin-2 (7.5 million IU twice a day)
Study: 10068580
Drug: Low-dose subcutaneous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose subcutaneous interleukin-2 (1.5 million IU twice a day)
Study: 7478680
Drug: Morphine solution
Normalized name: morphine Injectable Solution
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine solution taken at 4-hourly intervals for 7 days under direct nursing supervision
Study: 7478680
Drug: Morphine solution
Normalized name: morphine Injectable Solution
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine solution
Study: 7443365
Drug: Minimal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal treatment control
Study: 17209188
Drug: Iron supplement
Normalized name: Iron supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplement (100 mg Fe/d as ferrous gluconate)
Study: 15182139
Drug: Medication taking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication taking behavior
Study: 8739025
Drug: Tepoxalin (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tepoxalin (35 to 300 mg)
Study: 1764497
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with nitrendipine (10-40 mg/day), enalapril (5-20 mg/day), and hydrochlorothiazide (12.5-25 mg/day) as necessary.
Study: 20064822
Drug: RAAS inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAAS inhibitors
Study: 27753650
Drug: Pregabalin CR
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin CR (82.5 to 660 mg/d)
Study: 25541333
Drug: adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: adalimumab 40 mg every other week for 24 weeks, then open-label adalimumab for up to 5 years
Study: 19532100
Drug: Indapamide and
Normalized name: Indapamide and perindopril only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide and ACE-inhibitor (if needed)
Study: 19532100
Drug: ACE-inhibitor and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-inhibitor and angiotensin receptor blocker therapy
Study: 19532100
Drug: Thiazide diuretics,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide diuretics, ACE-inhibitors, or angiotensin receptor blockers (if ACE-inhibitor intolerant)
Study: 17431603
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg tadalafil
Study: 11354304
Drug: Prosorba treatment
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prosorba treatment